XML 37 R55.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Business Combination - Narrative (Details)
$ / shares in Units, shares in Millions, $ in Millions
1 Months Ended 2 Months Ended 6 Months Ended
Nov. 21, 2019
USD ($)
shares
Oct. 01, 2019
USD ($)
Aug. 01, 2019
USD ($)
Oct. 01, 2018
USD ($)
Jul. 31, 2018
Dec. 11, 2017
Nov. 30, 2019
USD ($)
Sep. 30, 2019
$ / shares
Sep. 28, 2019
USD ($)
Mar. 30, 2019
USD ($)
Dec. 28, 2019
USD ($)
Nov. 20, 2019
Business Acquisition [Line Items]                        
Consideration transferred $ 69.3                      
Ownership percentage 78.00%                      
Goodwill                 $ 2,563.7   $ 2,594.2  
Equity interest in acquiree, remeasurement gain $ 3.2                      
Consideration related to equity method investment 17.9                      
Consideration related to newly acquired shares             $ 12.6          
Consideration, portion related to loan repayment 30.2                      
Business Combination, Consideration related to fair value of noncontrolling interest 8.6                      
Discount rate percentage                   0.120    
Emsor                        
Business Acquisition [Line Items]                        
Period of cumulative revenue to trigger payment of contingent consideration liability           2 years            
Faxitron | Developed technology                        
Business Acquisition [Line Items]                        
Weighted average period         9 years              
Faxitron | Customer relationships                        
Business Acquisition [Line Items]                        
Weighted average period         9 years              
Faxitron | Trade names                        
Business Acquisition [Line Items]                        
Weighted average period         8 years 3 months 18 days              
Focal Therapeutics                        
Business Acquisition [Line Items]                        
Consideration transferred   $ 12.5   $ 120.1                
Purchase price withheld       $ 14.0           $ 1.5    
Period for payment of contingent consideration liabilities       1 year                
Goodwill       $ 31.1                
Focal Therapeutics | Developed technology                        
Business Acquisition [Line Items]                        
Identifiable intangible assets       $ 83.1                
Weighted average period       11 years                
Focal Therapeutics | In-process research and development                        
Business Acquisition [Line Items]                        
Identifiable intangible assets       $ 11.4                
Focal Therapeutics | In-process research and development | Minimum | Discount Rate                        
Business Acquisition [Line Items]                        
Intangible assets, fair value (percentage)       15.50%                
Focal Therapeutics | In-process research and development | Maximum | Discount Rate                        
Business Acquisition [Line Items]                        
Intangible assets, fair value (percentage)       16.50%                
Focal Therapeutics | Trade names                        
Business Acquisition [Line Items]                        
Identifiable intangible assets       $ 2.7                
Weighted average period       13 years                
SuperSonic Imagine                        
Business Acquisition [Line Items]                        
Consideration transferred 12.6   $ 18.2                  
Equity interest in acquiree, Percentage     46.00%                  
Goodwill 28.7                      
Other assets $ 6.5                      
Percentage of outstanding shares acquired     46.00%                 50.00%
Cash tender offer price (per share) | $ / shares               $ 1.50        
Shares acquired | shares 7.6                      
Other Income                        
Business Acquisition [Line Items]                        
Income (loss) from equity method investments                 $ 3.3